<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204698</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 11690</org_study_id>
    <nct_id>NCT00204698</nct_id>
  </id_info>
  <brief_title>Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment</brief_title>
  <official_title>Identification of Molecular Markers of Inflammatory Mediators in Posterior Laryngitis Due to Laryngopharyngeal Reflux and Evolution With PPI Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PriCara, Unit of Ortho-McNeil, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposes to investigate prospectively, the presence of molecular markers for&#xD;
      inflammation in laryngopharyngeal reflux (LPR) patients and to study the effect of a proton&#xD;
      pump inhibitor (Aciphex) on these molecular markers.&#xD;
&#xD;
      The investigators will be evaluating a group of patients before and after treatment. This&#xD;
      group will be patients that have untreated laryngopharyngeal reflux diagnosed by&#xD;
      laryngoscopic assessment and a 24-hour probe.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      This study proposes to investigate prospectively, the presence of molecular markers for&#xD;
      inflammation in LPR patients and to study the effect of a proton pump inhibitor on these&#xD;
      molecular markers. This study will provide important data regarding the etiology of LPR. It&#xD;
      will also provide vital information about the present standard treatment for LPR and why it&#xD;
      is not universally successful.&#xD;
&#xD;
      Patient Selection Criteria:&#xD;
&#xD;
      The subject group will consist of 25 subjects who have untreated LPR diagnosed by&#xD;
      laryngoscopic assessment and 24-hour pH probe.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      The presence of proinflammatory cytokines will be measured at the gene and protein expression&#xD;
      levels from PL biopsies with gene specific semiquantitative reverse transcription-polymerase&#xD;
      chain reaction and Western Blot analysis.&#xD;
&#xD;
      Statistical Methods, Data Analysis, and Interpretation:&#xD;
&#xD;
      Null Hypothesis: There will be no difference in cytokine expression in the posterior larynx&#xD;
      in patients with laryngopharyngeal reflux after 10 weeks of treatment with Aciphex, a proton&#xD;
      pump inhibitor.&#xD;
&#xD;
      Alternative Hypothesis: There will be a difference in cytokine expression in the posterior&#xD;
      larynx in patients with laryngopharyngeal reflux after 10 weeks of treatment with Aciphex, a&#xD;
      proton pump inhibitor.&#xD;
&#xD;
      Effect size = 30% (based upon review of the literature for cytokines in inflammatory states)&#xD;
&#xD;
      Standard Deviation = 30&#xD;
&#xD;
      Standard Effect Size = effect size/standard deviation = 30/30 = 1&#xD;
&#xD;
      With an alpha of 0.05, power 0.1 (90% power), sample size should be 22. Therefore we have&#xD;
      chosen 25 subjects in case of error in molecular studies.&#xD;
&#xD;
      Paired t-tests will be utilized to compare differences between cytokine levels for&#xD;
      experimental group initiation and completion of medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The presence of proinflammatory cytokines will be measured at the gene and protein expression levels from PL biopsies with gene specific semiquantitative reverse transcription-polymerase chain reaction and western blot analysis.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Laryngopharyngeal Reflux</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects will be given active drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aciphex</intervention_name>
    <description>20 mg of aciphex taken twice daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject group will consist of 25 subjects who have untreated LPR diagnosed by&#xD;
             laryngoscopic assessment and 24-hour pH probe.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Thibeault, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Thibeault SL, Smith ME, Peterson K, Ylitalo-Moller R. Gene expression changes of inflammatory mediators in posterior laryngitis due to laryngopharyngeal reflux and evolution with PPI treatment: a preliminary study. Laryngoscope. 2007 Nov;117(11):2050-6.</citation>
    <PMID>17721405</PMID>
  </results_reference>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>January 11, 2008</last_update_submitted>
  <last_update_submitted_qc>January 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2008</last_update_posted>
  <responsible_party>
    <name_title>Susan Thibeault, Ph.D.</name_title>
    <organization>University of Utah</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Laryngopharyngeal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

